abemaciclib (LY2835219)
abemaciclib (LY2835219) 是一种口服可用的细胞周期依赖性激酶(CDK)抑制剂,针对 CDK4 (cyclin D1) 和 CDK6 (cyclin D3) 细胞周期通路,具有潜在的抗肿瘤活性。
abemaciclib (LY2835219) 是一种口服可用的细胞周期依赖性激酶(CDK)抑制剂,针对 CDK4 (cyclin D1) 和 CDK6 (cyclin D3) 细胞周期通路,具有潜在的抗肿瘤活性。
| Discription | abemaciclib (LY2835219) is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
|||||
|---|---|---|---|---|---|---|
| Targets |
|
|||||
| Cell Research |
|
| 目录号 | A12989 |
|---|---|
| 分子式 | C27H32F2N8 |
| 分子量 | 506.59 |
| CAS号 | 1231929-97-7 |
| SMILES | CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F |
| 其他名称 | LY 2835219, LY-2835219 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
| In vitro | DMSO | 6 mg/mL (11.84 mM) | |
| Water | Insoluble | ||
| Ethanol | 8 mg/mL (15.79 mM) | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 19.74 mL | 98.7 mL | 197.4 mL |
| 0.5 mM | 3.95 mL | 19.74 mL | 39.48 mL |
| 1 mM | 1.97 mL | 9.87 mL | 19.74 mL |
| 5 mM | 0.39 mL | 1.97 mL | 3.95 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2